Analysis of CK2 Signaling in White Matter Stroke

Stroke occurs primarily in the elderly, and axonal damage and white matter dysfunction are responsible for much of the disability observed after stroke. Casein kinase 2 (CK2) is a protein kinase expressed in the brain, including white matter, and regulates many cellular functions important for brain development and cellular homeostasis. On the other hand, upregulation of CK2 activity is associated with many diseases, including ischemic stroke. In summary, the CK2 signaling pathway and related molecules exert protective or deleterious effects in ischemic stroke, particularly related to oxidative stress. Importantly, the downstream effectors of CK2 may serve as potential targets against ischemic stroke.

Fig. 1. CK2 inhibition confers white matter functional protection against ischemia by differentially regulating the CDK5 and AKT signaling pathways. (Baltan et al., 2018)

Our Services

Ace Therapeutics' team of highly skilled and experienced researchers utilizes state-of-the-art technology and cutting-edge methods to help clients elucidate the role and molecular mechanisms in white matter fractions following ischemia, and develop therapeutic options to protect the entire brain by treating white matter components against ischemia.

Assessment the Effects of CK2 Inhibitors in White Matter Stroke

We can investigate the mechanism by which CK2 inhibition protects white matter from ischemic injury by analyzing the effects of the CK2 inhibitor on mouse optic nerve (MON) cellular components. We aim to help our clients develop CDK5 inhibitors as potential therapeutic targets for the protection of white matter in MONs.

• We use immunohistochemistry and glial cell-specific antibodies combined with confocal imaging to assess the expression and localization of CK2 in MONs to support a biological basis for the action of CK2 inhibitors in MONs.
• We evaluate the effects of CK2 inhibition on nuclear morphology, oligodendrocytes, and the axonal cytoskeleton.

Analysis of the CK2-CDK5 and AKT/GSK3β signaling pathways

We use siRNA targeting the CK2α subunit to identify downstream molecules involved in CK2 signaling. Through a series of experiments, we can analyze the differential regulation of CDK5 and AKT/GSK3β signaling pathways by CK2 inhibition and its protective effects on post-ischemic white matter. We aim to help clients develop new targets to inform therapeutic choices for stroke.

Our Advantages

• Our team of experts has many years of experience in the field of stroke and an in-depth understanding of the molecular mechanisms of stroke.
• Our state-of-the-art equipment and facilities allow us to perform high-resolution imaging, molecular analysis, and functional assessment of axonal recovery.
• Our analysis services cover a wide range of experimental approaches, including functional assays, molecular analysis and structural evaluation.
• Our services not only help clients analyze the underlying mechanisms of CK2 signaling in white matter stroke, but also discover potential therapeutic targets.

Ace Therapeutics provides comprehensive analysis services to elucidate the role of CK2 signaling in white matter stroke. Through advanced methodologies and partnerships, we help our clients develop CK2 as a new potential target for the treatment of stroke. If you are interested in our services, please do not hesitate to contact us!

1. Baltan, S., et al. (2018). CK2 inhibition protects white matter from ischemic injury. Neuroscience letters, 687, 37-42.